ClinicalTrials.gg
CompletedNCT03817424Updated Dec 13, 2024

A Study to Evaluate VIB7734 in Participants With Systemic Lupus Erythematosus (SLE), Cutaneous Lupus Erythematosus (CLE), Sjogren's Syndrome, Systemic Sclerosis, Polymyositis, and Dermatomyositis

A Phase 1 interventional study of VIB7734 and Placebo in Systemic Lupus Erythematosus, Cutaneous Lupus Erythematosus and Sjogren's Syndrome, sponsored by Amgen. Completed at 30 sites in 3 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-12-13.

Sponsored by Amgen · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Jul 2020, 6 years 3 months ago, and no results have been posted to the registry.
Phase
Phase 1
Study type
Interventional
Enrollment
31
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

The purpose of this study is to evaluate the safety and tolerability of escalating, multiple subcutaneous (SC) doses of VIB7734 in participants with Systemic Lupus Erythematosus (SLE), Cutaneous Lupus Erythematosus (CLE), Sjogren's Syndrome, Systemic Sclerosis, Polymyositis, and Dermatomyositis.

Read the detailed description

This study will have 3 periods: screening, treatment period, and extended follow-up. The screening period is 28 days. A total of 32 participants will be enrolled in 3 cohorts with 8 participants in Cohort 1, and 12 participants each in Cohorts 2 and 3. In Cohort 1, participants will be randomized in a 3:1 ratio to receive VIB7734 or matching placebo by injection every 4 weeks (q4w) for a total of 3 doses on Days 1, 29, and 57. In Cohorts 2 and 3, participants diagnosed with lupus only will be randomized in a 2:1 ratio to receive VIB7734 or matching placebo by injection q4w for 3 doses on Days 1, 29, and 57. Participants will be followed until at least Day 141. After the Day 141 visit, participants will exit the study if participants meets adequate plasmacytoid dendritic cells (pDCs). If an adequate pDC level does not meet at Day 141 visit, the participant will continue the follow-up for pDC repletion until they meet the protocol defined adequate pDC level or Day 337 visit has been reached.

Study acquired from Horizon in 2024. Originally Viela Bio was the sponsor.

02

Conditions studied

  • Systemic Lupus Erythematosus
  • Cutaneous Lupus Erythematosus
  • Sjogren's Syndrome
  • Systemic Sclerosis
  • Polymyositis
  • Dermatomyositis
03

In context

Lupus Erythematosus, Systemic

1,207 studies on the registry are indexed under Lupus Erythematosus, Systemic; 405 are open to participants now.

This study's enrollment of 31 is below the median of 52 across 876 interventional studies indexed under Lupus Erythematosus, Systemic.

Browse Lupus Erythematosus, Systemic studies →

Lead sponsor

Amgen is the lead sponsor of 1,047 studies on the registry; 52 are open to participants now.

Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants aged 18 through 75 years at the time of screening
  • Participants with at least one of the following diagnoses:

    1. Systemic Lupus Erythematosus
    2. Cutaneous lupus erythematosus, including acute CLE, subacute CLE, and discoid lupus erythematosus
    3. Sjogren's syndrome (for Cohort 1 only)
    4. Systemic sclerosis (for Cohort 1 only)
    5. Probable or definite polymyositis (for Cohort 1 only)
    6. Probable or definite dermatomyositis (for Cohort 1 only)
  • For Cohorts 2 and 3 only: Participants with CLASI activity score greater than or equal to (>=) 8 at both Visits 1 (screening) and 2 (baseline)
  • For Cohorts 2 and 3 only: a skin lesion amenable to punch skin and willingness of the participant to undergo skin biopsy at two time points
  • For Cohorts 2 and 3 only: photographs of skin lesions must be submitted for review to confirm the diagnosis of SLE or CLE with active skin lesions confirmation of the diagnosis by the central reviewer must be received prior to randomization
  • Females of and nonsterilized males who are ready to use protocol defined methods

Exclusion criteria

Exclusion Criteria:

  • Severe manifestations of the diseases under study that could impact the participant safety
  • Known history of a primary immunodeficiency or an underlying condition such as known (HIV) infection, a positive result for HIV infection, splenectomy, or any underlying condition that predisposes the participant to infection
  • At screening, have adequate central laboratory test results: greater than (>) 2.5 x (ULN); alanine transaminase >2.5 x ULN; total 1.5 x ULN; total immunoglobulin \< 500 gram/decilitre; less than (\<) 1,000/μL; count \< 85,000/μL; \< 10 g/dL; glycosylated haemoglobin > 8 percent (%); total lymphocyte count \< 300 cells/mm\^3; \< 50 mL/min/1.73 m\^2; plasmacytoid dendritic cells (pDC) level \< 0.02% of peripheral blood mononuclear cells (PBMCs)
  • Positive test for chronic infection at screening and for virus antibody
  • History of or active tuberculosis (TB), or a positive QuantiFERON®-TB Gold test at screening; a primary immunodeficiency or an underlying condition such as known human immunodeficiency virus (HIV) infection, a positive result for HIV infection per central laboratory; cancer; cardiac disease
  • Herpes zoster infection within 3 months before randomization and/or any severe herpes virus family infection at any time prior to randomization
  • Any acute illness or evidence of clinically significant active infection, such as fever >= 38.0 degrees Celsius (>= 100.5 degrees Fahrenheit) at screening (Visit 1) or Day 1 (Visit 2)
  • Cohorts 2 and 3 only: use of Group 1 (super-high potency) or Group 2 (high potency) topical
  • Receipt of a within 4 weeks prior to Day 1
  • Cohorts 2 and 3 only: have received changing doses of mycophenolate mofetil, methotrexate, leflunomide, azathioprine, or non-steroidal topical within 28 days before study Day 1 or changing doses of oral or topical corticosteroids within 14 days before study Day 1
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anaemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
31 participants (actual)

Study arms

  • Experimental
    Cohort 1: VIB7734 Dose 1

    Participants will receive VIB7734 Dose 1 via injection q4w for a total of 3 doses on Days 1, 29, and 57.

    Drug: VIB7734

  • Experimental
    Cohort 2: VIB7734 Dose 2

    Participants will receive VIB7734 Dose 2 via injection q4w for a total of 3 doses on Days 1, 29, and 57.

    Drug: VIB7734

  • Experimental
    Cohort 3: VIB7734 Dose 3

    Participants will receive VIB7734 Dose 3 via injection q4w for a total of 3 doses on Days 1, 29, and 57.

    Drug: VIB7734

  • Placebo comparator
    Placebo

    Participants will receive placebo matching to VIB7734 via injection q4w for a total of 3 doses on Days 1, 29, and 57.

    Drug: Placebo

Interventions

  • Participants will receive VIB7734 via injection.

    Also known as: MEDI7734

  • DrugPlacebo

    Participants will receive placebo matching to VIB7734 via injection.

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs)

    Time frame: Day 1 up to Day 337

  2. Number of Participants With Adverse Events of Special Interest (AESIs)

    Time frame: Day 1 up to Day 337

  3. Number of Participants With Laboratory Abnormalities Reported as TEAEs

    Time frame: Day 1 up to Day 337

  4. Number of Participants With Vital Sign Abnormalities Reported as TEAEs

    Time frame: Day 1 up to Day 337

  5. Number of Participants With 12-Lead Electrocardiogram Abnormalities Reported as TEAEs

    Time frame: Day 1 up to Day 337

Secondary outcomes

  1. Maximum Observed Serum Concentration (Cmax) of VIB7734 Maximum Observed Serum Concentration (Cmax) of VIB7734

    Time frame: Days 1 (pre-dose), 8, 15, 29 (pre-dose), 36, 43, 57 (pre-dose), 64, 71, 85, 113, 141, 169, 197, 225, and 253

  2. Area Under the Concentration-time Curve (AUC) of VIB7734

    Time frame: Days 1 (pre-dose), 8, 15, 29 (pre-dose), 36, 43, 57 (pre-dose), 64, 71, 85, 113, 141, 169, 197, 225, and 253

  3. Systemic Clearance (CL) of VIB7734

    Time frame: Days 1 (pre-dose), 8, 15, 29 (pre-dose), 36, 43, 57 (pre-dose), 64, 71, 85, 113, 141, 169, 197, 225, and 253

  4. Terminal Half-life (t1/2) of VIB7734

    Time frame: Days 1 (pre-dose), 8, 15, 29 (pre-dose), 36, 43, 57 (pre-dose), 64, 71, 85, 113, 141, 169, 197, 225, and 253

  5. Number of Participants With Positive Anti-Drug Antibodies of VIB7734

    Time frame: Day 1 up to Day 309

  6. Change from Baseline in Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) Activity Score (Cohorts 2 and 3)

    Time frame: Day 1 up to Day 253

  7. Blood Levels of pDCs

    Time frame: Day 1 up to Day 337

07

Study locations

30 sites
  • Viela Bio Investigative Site
    Anniston, Alabama 36201, United States
  • Viela Bio Investigative Site
    Birmingham, Alabama 35294, United States
  • Viela Bio Investigative Site
    Los Angeles, California 90022, United States
  • Viela Bio Investigative Site
    Upland, California 91786, United States
  • Viela Bio Investigative Site
    Danbury, Connecticut 06810, United States
  • Viela Bio Investigative Site
    Fort Lauderdale, Florida 33309, United States
  • Viela Bio Investigative Site
    Hialeah, Florida 33016, United States
  • Viela Bio Investigative Site
    Jacksonville, Florida 32216, United States
  • Viela Bio Investigative Site
    Miami Lakes, Florida 33014, United States
  • Viela Bio Investigative Site
    Saint Petersburg, Florida 33710, United States
  • Viela Bio Investigative Site
    Lawrenceville, Georgia 30046, United States
  • Viela Bio Investigative Site
    Great Neck, New York 11021, United States
  • Viela Bio Investigative Site
    Charlotte, North Carolina 28204, United States
  • Viela Bio Investigative Site
    Durham, North Carolina 27713, United States
  • Viela Bio Investigative Site
    Duncansville, Pennsylvania 16635, United States
  • Viela Bio Investigative Site
    Philadelphia, Pennsylvania 19104, United States
  • Viela Bio Investigative Site
    Memphis, Tennessee 38119, United States
  • Viela Bio Investigative Site
    Allen, Texas 75013, United States
  • Viela Bio Investigative Site
    Mesquite, Texas 75150, United States
  • Viela Bio Investigative Site
    Białystok, Poland
  • Viela Bio Investigative Site
    Bydgoszcz, Poland
  • Viela Bio Investigative Site
    Kraków, Poland
  • Viela Bio Investigative Site
    Poznań, Poland
  • Viela Bio Investigative Site
    Rzeszów, Poland
  • Viela Bio Investigative Site
    Warsaw, Poland
  • Viela Bio Investigative Site
    Wrocław, Poland
  • Viela Bio Investigative Site
    Barcelona, Spain
  • Viela Bio Investigative Site
    Bilbao, Spain
  • Viela Bio Investigative Site
    Madrid, Spain
  • Viela Bio Investigative Site
    Sevilla, Spain
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Dec 13, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03817424
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Jan 25, 2019
Start date
Dec 13, 2018
Primary completion
Jul 20, 2020
Completion
Jul 20, 2020
Last update
Dec 13, 2024

Study contacts

MD
study director · Amgen

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Daxdilimab

Start the discussion